CT scan

Global Computed Tomography (CT) Scanners Strategic Business Report 2024-2030: Superior Attributes over Other Imaging Technologies Drive Steady Adoption of CT Scanners

Retrieved on: 
Tuesday, February 20, 2024

DUBLIN, Feb. 20, 2024 /PRNewswire/ -- The "Computed Tomography (CT) Scanners - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 20, 2024 /PRNewswire/ -- The "Computed Tomography (CT) Scanners - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • CT scanners play a crucial role in enabling advanced non-invasive patient care by meeting unique imaging needs, particularly highlighted during the COVID-19 pandemic.
  • The impact of COVID-19 on the medical imaging market has been significant, with a spotlight on lung ultrasound driving demand for portable ultrasound and CT imaging.
  • The global market outlook for CT scanners is promising, with high-slice CT scanners expected to drive future growth, especially in oncology applications.

NDT and Inspection Market worth $18.4 billion by 2029- Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, February 15, 2024

The power Generation vertical of the NDT and Inspection market is predicted to register the highest market share between 2024-2029.

Key Points: 
  • The power Generation vertical of the NDT and Inspection market is predicted to register the highest market share between 2024-2029.
  • NDT and Inspection market for the Asia Pacific region to register the highest CAGR between 2024 and 2029 forecast.
  • The Asia Pacific region is poised to emerge as the fastest-growing market for NDT and inspection, driven by rapid infrastructural developments.
  • However, challenges such as pricing pressures pose a limitation to the growth of the NDT and inspection industry in Asia Pacific.

NDT and Inspection Market worth $18.4 billion by 2029- Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, February 15, 2024

The power Generation vertical of the NDT and Inspection market is predicted to register the highest market share between 2024-2029.

Key Points: 
  • The power Generation vertical of the NDT and Inspection market is predicted to register the highest market share between 2024-2029.
  • NDT and Inspection market for the Asia Pacific region to register the highest CAGR between 2024 and 2029 forecast.
  • The Asia Pacific region is poised to emerge as the fastest-growing market for NDT and inspection, driven by rapid infrastructural developments.
  • However, challenges such as pricing pressures pose a limitation to the growth of the NDT and inspection industry in Asia Pacific.

Nanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty Liver

Retrieved on: 
Tuesday, February 13, 2024

PETACH TIKVA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd., received 510(k) clearance by the U.S. Food and Drug Administration (FDA) for HealthFLD, an artificial intelligence (AI) software that provides automated qualitative and quantitative analysis of liver attenuation from routine contrast and non-contrast chest and abdomen CT scans in patients between the ages of 18 to 75. HealthFLD is intended to support clinicians in the detection of fatty liver, correlated with hepatic steatosis, an early sign of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD).

Key Points: 
  • HealthFLD is intended to support clinicians in the detection of fatty liver, correlated with hepatic steatosis, an early sign of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD).
  • MASLD is commonly asymptomatic until it progresses to advanced liver fibrosis, and the current gold standard for diagnosis is a liver biopsy, which is invasive and costly.
  • HealthFLD was designed to help clinicians in the assessment and analysis of fatty liver in the general population from routine CT scans.
  • It’s promising to have a liver solution available that may help evaluate early signs of illness from routine imaging.”
    The HealthFLD clearance is the third product across the Nanox AI suite of population health solutions to receive FDA clearance.

Squamish Hospital Foundation fundraising for a CT scanner now a reality following $900k commitment from Woodfire LNG

Retrieved on: 
Monday, February 12, 2024

Squamish, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Squamish Hospital Foundation announces that Woodfibre LNG has committed $900,000 toward the purchase of a new Computed Tomography (CT) scanner at Squamish General Hospital.

Key Points: 
  • Squamish, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Squamish Hospital Foundation announces that Woodfibre LNG has committed $900,000 toward the purchase of a new Computed Tomography (CT) scanner at Squamish General Hospital.
  • Having a CT scanner at Squamish General Hospital will provide improved access to important diagnostic health services for residents of Squamish and the Sea-to-Sky corridor.
  • We sincerely thank everyone.”
    The Squamish Hospital Foundation has been fundraising for a CT scanner and have raised $200,000 towards its purchase.
  • “Woodfibre LNG is tremendously pleased to complete the funding required to purchase a CT scanner for the Squamish Hospital.

United States Contrast Media Market Size, Share & Trends Analysis Report 2023: Chronic Diseases and Comorbidities Increase Demand for Imaging Tests - Forecast to 2030

Retrieved on: 
Monday, January 22, 2024

Contrast Media Market Size, Share & Trends Analysis Report by Modality (Modality, Ultrasound, Magnetic Resonance Imaging (MRI), X-ray/Computed Tomography (CT Scan)), Type, Application, and Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Contrast Media Market Size, Share & Trends Analysis Report by Modality (Modality, Ultrasound, Magnetic Resonance Imaging (MRI), X-ray/Computed Tomography (CT Scan)), Type, Application, and Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. contrast media market size is expected to reach USD 3.36 billion by 2030, registering a CAGR of 4.1% from 2023 to 2030
    The increasing burden of chronic diseases is creating a demand for diagnostic imaging procedures, which, in turn, is driving the market growth.
  • Imaging tests, such as MRI, have become an integral part of the diagnosis for most diseases, and large-scale penetration of imaging technology in healthcare has increased the demand for contrast media in the U.S. market.
  • Hence, the increasing prevalence of complex comorbidities and long-term diseases is one of the major drivers of imaging tests and contrast agents; thus, contributing to the market growth.

ClearPoint Neuro Announces FDA Clearance for SmartFrame OR™ Stereotactic System

Retrieved on: 
Tuesday, January 16, 2024

SOLANA BEACH, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510(k) clearance for its SmartFrame OR™ Stereotactic System.

Key Points: 
  • SOLANA BEACH, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510(k) clearance for its SmartFrame OR™ Stereotactic System.
  • The SmartFrame OR Stereotactic System is composed of two main components: the SmartFrame OR, and the ClearPointer™ Optical Navigation Wand.
  • The ClearPointer is intended to be used in conjunction with the SmartFrame OR and a compatible stereotactic optical navigation system for patient registration and navigation.
  • “More than 95% of all stereotactic neuro-navigation procedures take place in the OR, supporting DBS, Laser Ablation, Biopsy, sEEG, and more.

2023 Year in Review: TSA highlights a year of innovation and improvements to security effectiveness, efficiency and the passenger experience

Retrieved on: 
Friday, January 12, 2024

WASHINGTON, Jan. 12, 2024 /PRNewswire/ -- The Transportation Security Administration (TSA) marked another successful year in 2023, making significant strides to improve transportation security effectiveness, efficiency and enhance the aviation passenger experience.

Key Points: 
  • WASHINGTON, Jan. 12, 2024 /PRNewswire/ -- The Transportation Security Administration (TSA) marked another successful year in 2023, making significant strides to improve transportation security effectiveness, efficiency and enhance the aviation passenger experience.
  • In 2023, TSA screened a record 858+ million passengers, an average of 2.4 million daily passengers at airport security checkpoints across the country.
  • As a result, TSA has seen a significant reduction in attrition and improvement in the ability to recruit for open positions.
  • Continued to purchase and deploy innovative checkpoint technologies that improve security effectiveness and efficiency, while enhancing the passenger experience.

Chertoff Group Announces Promotions and New Transportation & Innovation Practice

Retrieved on: 
Tuesday, January 9, 2024

The firm’s Federal Strategy & Security practice helps companies identify and mitigate risk, coordinate and plan business operations and understand and navigate growth and capture.

Key Points: 
  • The firm’s Federal Strategy & Security practice helps companies identify and mitigate risk, coordinate and plan business operations and understand and navigate growth and capture.
  • The firm’s Transportation & Innovation practice area will build on its existing transportation security and national level remote screening for checkpoint and checked baggage Computed Tomography (CT).
  • The Chertoff Group has two patents granted in this area, with several others in provisional status.
  • Chertoff Group Co-Founder and CEO Chad Sweet said, “Congratulations to Lee, Ben and Aaron.

New Guidelines on Men with Erectile Dysfunction and Cardiac Health Published in the Journal of Sexual Medicine Concludes PDE-5 Inhibitors are Still Safe for the Cardiovascular System

Retrieved on: 
Thursday, January 4, 2024

Their summary and guidelines have now been published in the Journal of Sexual Medicine.

Key Points: 
  • Their summary and guidelines have now been published in the Journal of Sexual Medicine.
  • They determined that PDE-5 inhibitors are still safe for the cardiovascular system.
  • The conference was funded by an unrestricted grant from Sanofi to readdress the cardiovascular workup of men presenting with ED and the cardiovascular safety of the phosphodiesterase-5 (PDE-5) inhibitors for treating ED.
  • Patients with ED should be characterized as low-risk, intermediate (or indeterminable), or high-risk of developing a cardiac event with sexual activity.